Smoore International's subsidiary, Transcend Biopharma, has its ANDA accepted by the FDA, potentially granting it 180 days of market exclusivity

Sep.25.2025

Smoore International announced that the U.S. FDA has accepted the Abbreviated New Drug Application (ANDA) for its Breo® Ellipta® 100/25 generic drug, submitted by its wholly-owned subsidiary, Transpire Bio. Transpire Bio stated that if approved, it is expected to receive 180 days of market exclusivity. In the United States, Breo® Ellipta® is already approved for the maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD).

Key Points:

·Development of the Event: Smoore International (6969.HK) wholly-owned subsidiary, ChuanSi Biotech, has had its generic version of Breo® Ellipta® 100/25, fluticasone furoate / vilanterol inhalation powder ANDA, accepted by the U.S. FDA.

·Uniqueness of the application: According to FDA public records, ChuanSi Biotech claims to be the first company to submit an ANDA with a Paragraph IV Certification under the Hatch-Waxman Act.

·Market potential and scale: If the ANDA is approved, ChuanSi Biotech expects to have 180 days of market exclusivity; the branded drug Breo® Ellipta® had annual sales of $2.02 billion in the U.S. in 2024 (IQVIA data), and is used for maintenance treatment in asthma and COPD patients.

·Corporate layout support: Smoore International's mid-term report shows that ChuanSi Biotech has established an inhalation product R&D center near Miami, Florida (with full process development capabilities), and has partnered with a top CDMO to build manufacturing capabilities for pharmaceutical devices in the U.S.

On September 25, 2025, Smoore International (6969.HK) announced via Globe Newswire and social platform X News that its wholly-owned subsidiary, Transpire Bio, had its Abbreviated New Drug Application (ANDA) for a generic version of the fluticasone furoate/vilanterol inhalation powder (Breo® Ellipta®1 100/25) accepted by the US Food and Drug Administration (FDA).

Smoore International's subsidiary, Transcend Biopharma, has its ANDA accepted by the FDA, potentially granting it 180 days of market exclusivity — Image source: Smoore social platform X

According to FDA public records, Transcend Biologics believes it is the first company to submit an ANDA with a Paragraph IV Certification under the Hatch-Waxman Act.

According to a press release by Chuant Biotech, if their ANDA is approved by the FDA, they expect to be eligible for a 180-day market exclusivity period. In the United States, Breo® Ellipta® is approved for maintenance treatment of asthma patients as well as maintenance treatment for patients with chronic obstructive pulmonary disease (COPD). According to IQVIA data, Breo® Ellipta® had annual US sales of $2.02 billion in 2024.

In its mid-year report for 2025, Smoore International stated that its nebulization subsidiary, Transcend Biotech, has established an outstanding inhalation product research and development center near Miami, Florida. The center possesses all capabilities for product development, and Transcend Biotech is actively collaborating with leading Contract Development and Manufacturing Organizations (CDMOs) worldwide to establish manufacturing capabilities for drug-device combination products in the United States.

References:

[1] Transpire Bio’s ANDA for Generic Breo® Ellipta® Accepted for Filing By the U.S. FDA

Also Read:

[1] The U.S. FDA has launched a pilot program for PMTA review of nicotine pouches to expedite the approval process and enhance regulatory efficiency

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn

Notice

1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

Copyright

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

AI Assistance Disclaimer

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com